Granisetron Market Size, Share, Trends, Growth Outlook

Granisetron Market is estimated to increase at a Compounded Annual Growth Rate of 5.3% CAGR over the forecast period from 2024 to 2030

The Granisetron Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Transdermal system, Injection, Oral), By Application (Chemotherapy, Post-operative), By Distribution Channel (Hospitals, Drug Stores, Others).

An Introduction to Granisetron Market in 2024

Granisetron, a selective 5-HT3 receptor antagonist, is a cornerstone therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). In 2024, the market for granisetron is characterized by a diverse range of formulations, including oral tablets, injectable solutions, transdermal patches, and oral soluble films, offering flexibility and convenience for patients and healthcare providers. Continuous advancements in drug delivery technologies, such as extended-release formulations and patient-controlled systems, aim to optimize the pharmacokinetic profile of granisetron, ensuring sustained antiemetic efficacy and improved adherence to treatment regimens. Additionally, combination therapies incorporating granisetron with other antiemetics or supportive care agents further enhance the management of nausea and vomiting associated with cancer chemotherapy and surgical procedures. With an increasing emphasis on patient-centered care and quality of life outcomes, granisetron remains a cornerstone therapy in the prevention and management of CINV and PONV, providing relief for millions of patients undergoing cancer treatment and surgery worldwide.

Market Trend: Expansion of Indications and Formulations

A significant trend in the market for granisetron is the expansion of indications and formulations. Originally developed as an antiemetic agent for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), granisetron is witnessing a trend towards broader applications across various therapeutic areas such as postoperative nausea and vomiting (PONV), radiation-induced nausea and vomiting (RINV), and gastroenterological disorders. Additionally, there's a growing demand for alternative formulations of granisetron, including extended-release formulations, transdermal patches, and oral dissolvable tablets, offering patients and healthcare providers more options for effective nausea and vomiting management in diverse clinical settings.

Market Driver: Increasing Incidence of Chemotherapy-Induced Nausea and Vomiting

The primary driver propelling the market for granisetron is the increasing incidence of chemotherapy-induced nausea and vomiting (CINV). With chemotherapy being a cornerstone of cancer treatment, CINV remains a significant side effect that negatively impacts patients' quality of life and treatment adherence. Granisetron, as a potent and selective 5-HT3 receptor antagonist, plays a crucial role in preventing and managing CINV by inhibiting serotonin signaling in the gastrointestinal tract and central nervous system. The growing prevalence of cancer worldwide, along with advancements in oncology therapies that prolong survival but often induce CINV, drives the demand for granisetron as an essential component of antiemetic regimens in cancer care.

Market Opportunity: Expansion into Emerging Markets and Patient Populations

An untapped opportunity within the market for granisetron lies in the expansion into emerging markets and patient populations. While granisetron is well-established in developed markets for managing CINV, there's potential to penetrate emerging markets in regions such as Asia-Pacific, Latin America, and the Middle East, where cancer incidence rates are rising, and access to antiemetic therapies may be limited. Additionally, there's an opportunity to explore new patient populations beyond oncology, such as patients undergoing surgical procedures, receiving radiotherapy, or experiencing nausea and vomiting due to gastroenterological conditions. By expanding market reach and diversifying indications, granisetron manufacturers can address unmet medical needs, improve patient access to essential therapies, and drive market growth in the global antiemetics market. Embracing the opportunity to expand into emerging markets and patient populations aligns with advanced cancer-supportive care and enhances patient outcomes worldwide.

Granisetron Market Share Analysis: Transdermal System

The transdermal system segment within the Granisetron market is experiencing the most rapid growth. This method of delivery involves administering Granisetron through the skin via patches or similar mechanisms. The appeal of transdermal systems lies in their convenience, providing a non-invasive and patient-friendly alternative to injections or oral medications. Patients undergoing chemotherapy or post-operative care often prefer transdermal systems due to their ease of use and avoidance of potential side effects associated with other routes of administration. Additionally, transdermal delivery ensures a more consistent and sustained release of the medication, enhancing its efficacy. As a result, hospitals, drug stores, and other distribution channels are witnessing increasing demand for Granisetron transdermal systems, driving significant growth in this segment of the market.

Granisetron Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAkorn Operating Company LLC, Cipla Ltd, Dr. Reddy's Laboratories Ltd, Fresenius SE & Co. KGaA, Heron Therapeutics Inc, Hikma Pharmaceuticals PLC, Kyowa Kirin Co. Ltd, Merck KGaA, Natco Pharma Ltd, Novartis AG, Viatris Inc

Granisetron Market Segmentation

By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Granisetron Market Companies

Akorn Operating Company LLC
Cipla Ltd
Dr. Reddy's Laboratories Ltd
Fresenius SE & Co. KGaA
Heron Therapeutics Inc
Hikma Pharmaceuticals PLC
Kyowa Kirin Co. Ltd
Merck KGaA
Natco Pharma Ltd
Novartis AG
Viatris Inc

Reasons to Buy the Granisetron Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Granisetron Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Granisetron Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Granisetron Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Granisetron Market Size Outlook, $ Million, 2021 to 2030
3.2 Granisetron Market Outlook by Type, $ Million, 2021 to 2030
3.3 Granisetron Market Outlook by Product, $ Million, 2021 to 2030
3.4 Granisetron Market Outlook by Application, $ Million, 2021 to 2030
3.5 Granisetron Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Granisetron Industry
4.2 Key Market Trends in Granisetron Industry
4.3 Potential Opportunities in Granisetron Industry
4.4 Key Challenges in Granisetron Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Granisetron Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Granisetron Market Outlook by Segments
7.1 Granisetron Market Outlook by Segments, $ Million, 2021- 2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others

8 North America Granisetron Market Analysis and Outlook To 2030
8.1 Introduction to North America Granisetron Markets in 2024
8.2 North America Granisetron Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Granisetron Market size Outlook by Segments, 2021-2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others

9 Europe Granisetron Market Analysis and Outlook To 2030
9.1 Introduction to Europe Granisetron Markets in 2024
9.2 Europe Granisetron Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Granisetron Market Size Outlook by Segments, 2021-2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others

10 Asia Pacific Granisetron Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Granisetron Markets in 2024
10.2 Asia Pacific Granisetron Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Granisetron Market size Outlook by Segments, 2021-2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others

11 South America Granisetron Market Analysis and Outlook To 2030
11.1 Introduction to South America Granisetron Markets in 2024
11.2 South America Granisetron Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Granisetron Market size Outlook by Segments, 2021-2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others
12 Middle East and Africa Granisetron Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Granisetron Markets in 2024
12.2 Middle East and Africa Granisetron Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Granisetron Market size Outlook by Segments, 2021-2030
By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Akorn Operating Company LLC
Cipla Ltd
Dr. Reddy's Laboratories Ltd
Fresenius SE & Co. KGaA
Heron Therapeutics Inc
Hikma Pharmaceuticals PLC
Kyowa Kirin Co. Ltd
Merck KGaA
Natco Pharma Ltd
Novartis AG
Viatris Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Transdermal system
Injection
Oral
By Application
Chemotherapy
Post-operative
By Distribution Channel
Hospitals
Drug Stores
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)